Target Leukemia Treatment Shows Promise
Sacramento, CA - Noriko Satake, UC Davis pediatric oncologist and researcher, has demonstrated in laboratory studies that a new, targeted treatment for leukemia is effective. The research was published in the British Journal of Haematology.
“We identified a novel molecular target that is important for the growth of precursor B-cell acute lymphoblastic leukemia (ALL), the most common cancer in children,” Satake said. “We developed a unique treatment approach using a drug that blocks the target molecule and kills leukemia cells, a nanoparticle vehicle that carries the drug, and an antibody driver that delivers the nanocomplexes (drug-loaded nanoparticles) to leukemia cells.
“We showed great efficacy of these new drug nanocomplexes on a cell line and on primary leukemia samples,” she added. “We also demonstrated that they had minimal toxicities on normal blood cells.”
Adding to the impact of the research, Satake and her colleagues found that the drug nanocomplexes worked very well when combined with conventional chemotherapy drugs vincristine and doxorubicin. This means that the new drug complexes can replace some of the toxic chemotherapy drugs currently used to treat patients.
Based on these results, the researchers conducted additional work leading to development of another drug, which is more suitable for clinical use. They plan to file a patent on the drug and then work toward clinical trials. Satake said the approach could apply to many other cancers, including adult cancers. Continue>
Page | 1 2
Posted in: On The Horizon | November 14, 2014
New Treatment Options for Advanced-Stage Cancer Patients Revealed Through Next-Generation Sequencing Test
Posted in: On The Horizon | November 19, 2015
Posted in: On The Horizon | December 9, 2016